BioStock: Focus on phase IIb study expansion for RhoVac during Q1

For the drug developer RhoVac, the first quarter was characterized by the continued pandemic effects and the company’s activities to counteract these. Several US cancer centres have started their participation in the ongoing phase IIb trial BRaVac, and the company has continued to see great interest in drug candidate RV001. BioStock contacted CEO Anders Månsson to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/focus-on-phase-iib-study-expansion-for-rhovac-during-q1/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se